RecruitingPhase 1NCT07754331

Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

A Phase I, Single-Centre, Randomised, Single-dose, Open-label, 2-period, 2-way Crossover Study to Assess the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin in Participants With Kidney Failure

Sponsor

AstraZeneca

Enrollment

10 participants

Start Date

Aug 6, 2026

Study Type

INTERVENTIONAL

Conditions

Kidney Failure

Summary

The purpose of this study is to investigate the effect of HD on single oral dose PK, safety, and tolerability of balcinrenone/dapagliflozin to male and female participants with kidney failure on intermittent HD.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Balcinrenone/dapagliflozin for people with kidney failure. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBalcinrenone/dapagliflozin

Participants will be receiving balcinrenone/ dapagliflozin before or after hemodialysis

Locations(1)

Research Site

Orlando, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07754331

Related Trials

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

NCT044479116 locations

Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation

NCT07792317